Clinical trials sponsored by Avistone Biotechnology Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by Avistone Biotechnology Co., Ltd.

• A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
  NCT06046495 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
  NCT07336732 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
  NCT06574347 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
  NCT06343064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Avistone Biotechnology Co., Ltd. recruiting for?

Avistone Biotechnology Co., Ltd. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.